New Jersey is currently home to 1652 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337
Recruiting
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \[IHC\]2+/in situ hybridization \[ISH\]- and IHC 1+) population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Research Site 1111-0, Florham Park, New Jersey
Conditions: Metastatic Breast Cancer
Register for Updates
A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis
NCT05832151
Recruiting
The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastroparesis in adult patients. The main questions it aims to answer are: * To evaluate the efficacy of CIN-102 on symptoms of gastroparesis when given to patients with diabetic gastroparesis compared to a placebo * To evaluate the safety and tolerability of CIN-102 when given to patients with diabetic gastroparesis compared to a placebo Participants... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Allied Health Clinical Research Organization, LLC (AHCRO) - Englewood, Englewood, New Jersey
Conditions: Diabetic Gastroparesis
Register for Updates
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People with HPV-Positive Throat Cancer
NCT05491512
Recruiting
The purpose of this study is to find out if lower doses of radiation may help reduce the side effects of radiation therapy in combination with standard-of-care chemotherapy in people with HPV-positive throat cancer. The chemotherapy drugs used in this study include cisplatin, carboplatin, and 5-fluorouracil (5- FU), paclitaxel and abraxane- (Albumin-bound Paclitaxel).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: HPV, Throat Cancer, Oropharyngeal Carcinoma, Oropharyngeal Cancer, Human Papilloma Virus
Register for Updates
Phase 1/2 Study of REGN5458 in Adult Patients With Relapsed or Refractory Multiple Myeloma
NCT03761108
Recruiting
The main purpose of this study is to learn about the safety of REGN5458 and to find out what is the best dose of REGN5458 to give to patients with multiple myeloma. An additional purpose is to look for any signs that REGN5458 can treat cancer. The study is looking at several other research questions, including: * Side effects that may be experienced by people receiving REGN5458 * How REGN5458 works in the body * How much REGN5458 is present in the blood * How REGN5458 may work to treat cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
Conditions: Multiple Myeloma
Register for Updates
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
NCT02687906
Recruiting
A single dose infusion of Vabomere (meropenem-vaborbactam) is being tested for dose-finding, pharmacokinetics, safety, and tolerability in pediatric subjects from birth to less than 18 years of age with serious bacterial infections
Gender:
ALL
Ages:
17 years and below
Trial Updated:
02/27/2025
Locations: Rutger's University, New Brunswick, New Jersey
Conditions: Bacterial Infections
Register for Updates
PROPEL - A Prospective Observational Patient Registry to Evaluate ENPP1 and ABCC6 Deficiency
NCT06302439
Recruiting
The purpose of this prospective registry is to characterize the natural history of ectonucleotide pyrophosphatase/phosphodiesterase1(ENPP1) Deficiency and the infantile-onset form of adenosine triphosphate (ATP) binding cassette transporter protein subfamily C member 6 (ABCC6) Deficiency longitudinally. The registry will prospectively gather information about the genetic, biochemical, physiological, anatomic, radiographic, and functional manifestations (including patient reported outcomes \[PROs... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/26/2025
Locations: CLINILABS Drug Development Corp, Eatontown, New Jersey
Conditions: ATP-Binding Cassette Subfamily C Member 6 Deficiency, Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency
Register for Updates
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
NCT06028074
Recruiting
GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Rutgers Cancer Institute of NJ, New Brunswick, New Jersey
Conditions: Advanced Solid Malignancies
Register for Updates
Re-Connect Application for Smoking Cessation
NCT05224154
Recruiting
This series of studies will explore the acceptability, feasibility, and preliminary efficacy of making access to smartphone applications contingent on objective evidence of smoking abstinence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2025
Locations: Rowan University, Glassboro, New Jersey
Conditions: Smoking Cessation, Acceptability of Health Care, Nicotine Dependence, Cigarettes
Register for Updates
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
NCT04427384
Recruiting
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Gender:
ALL
Ages:
All
Trial Updated:
02/26/2025
Locations: Clinical Research dep. Davison Place. Englewood Health, Englewood, New Jersey
Conditions: Brain Tumor, Recurrent, Brain Tumor, Brain Tumor, Primary, Brain Tumor - Metastatic, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Adult Meningioma
Register for Updates
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
NCT06843967
Recruiting
The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, recurrent, and unresectable liposarcoma. This study will test different doses of mirdametinib in combination with a fixed dose of palbociclib to find the best safe dose for further testing.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma, Liposarcoma, Myxoid Liposarcoma, Round Cell Liposarcoma, Myxoid Pleomorphic Liposarcoma, Pleomorphic Liposarcoma, Unresectable Liposarcoma, Unresectable Dedifferentiated Liposarcoma
Register for Updates
Self-balancing Personal Exoskeleton for SCI (site 2)
NCT06814015
Recruiting
This study aims to demonstrate the safety and effectiveness of the personal exoskeleton in individuals with spinal cord injury (SCI).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Kessler Foundation, West Orange, New Jersey
Conditions: Spinal Cord Injuries (SCI), Paraplegia and Tetraplegia
Register for Updates
To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications
NCT06553027
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424, 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.
Gender:
ALL
Ages:
30 years and above
Trial Updated:
02/25/2025
Locations: Boro Neurology, Hopewell, New Jersey
Conditions: Parkinson Disease
Register for Updates